COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
  Global AdoptionAdoption
  Submit FeedbackFeedback (ES)66%0.34 [0.12-0.96]death4/11227/260Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment66%0.34 [0.12-0.96]4/11227/26066% improvementWang (RCT)-9%1.09 [0.54-2.18]death22/15810/78Improvement, RR [CI]TreatmentControlOlender59%0.41 [0.24-0.71]death24/312102/818Spinner (RCT)35%0.65 [0.18-2.40]death5/3844/200Pasquini16%0.84 [0.69-0.94]death14/2524/26Fried61%0.39 [0.15-0.99]death4/482,510/11,673Beigel (RCT)27%0.73 [0.52-1.03]death541521SOLIDARITY (RCT)5%0.95 [0.81-1.11]death301/2,743303/2,708Solh47%0.53 [0.39-0.70]death63/219202/424Flisiak49%0.51 [0.19-1.30]death5/12217/211Garibaldi20%0.80 [0.46-1.41]death23/30345/303Ullah-100%2.00 [0.67-5.94]death8/304/30Goldberg9%0.91 [0.70-1.17]hosp. time29113Tsuzuki9%0.91 [0.45-1.85]death9/7426/195Mahajan (RCT)-76%1.76 [0.46-6.82]death5/343/36Aghajani19%0.81 [0.46-1.46]death46945Arch20%0.80 [0.64-0.98]death203/1,491777/4,676Barrat-Due (DB RCT)0%1.00 [0.20-4.60]death3/374/53Ohl-6%1.06 [0.83-1.36]death143/1,172124/1,172Madan44%0.56 [0.33-0.95]death23/39827/260Tau​2 = 0.04; I​2 = 58.6%Late treatment22%0.78 [0.67-0.90]855/8,1664,182/24,44222% improvementAll studies22%0.78 [0.67-0.90]859/8,2784,209/24,70222% improvement20 remdesivir COVID-19 7/30/21Tau​2 = 0.04; I​2 = 58.6%; Z = 3.31 (p = 0.00046)Effect extraction pre-specifiedLower RiskIncreased Risk
Late Madan et al., medRxiv, doi:10.1101/2021.07.15.21260600 (Preprint) death, ↓44.4%, p=0.03 Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir
Details   Retrospective 1,262 hospitalized patients, 398 treated with remdesivir, showing unadjusted lower mortality with treatment, and a treatment delay-response relationship.
Late Ohl et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.14741 (Peer Reviewed) death, ↑6.0%, p=0.66 Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19
Details   Retrospective 5,898 hospitalized patients in the USA, 2,374 receiving remdesivir treatment, showing no significant difference in mortality, and a longer time to hospital discharge with treatment.
Late Barrat-Due et al., Annals of Internal Medicine, doi:10.7326/M21-0653 (Peer Reviewed) death, 0.0%, p=1.00 Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19
Details   Small RCT in Norway with 52 HCQ and 42 remdesivir patients, showing no significant differences with treatment. Add-on trial to WHO Solidarity. NCT04321616.
Late Arch et al., medRxiv, doi:10.1101/2021.06.18.21259072 (Preprint) death, ↓19.9%, p=0.03 Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study
Details   Prospective PSM analysis of remdesivir use in the UK showing statistically significantly lower mortality at 28 days. For unspecified reasons, the study prioritized short-term outcomes. Mortality at 14 days was also lower but not statistic..
Meta Liao et al., Journal of the Formosan Medical Association, doi:10.1016/j.jfma.2021.04.026 (Peer Reviewed) (meta analysis) meta-analysis Assessing Efficacy of Antiviral Therapy for COVID-19 Patients: A Case Study on Remdesivir with Bayesian Synthesis Design and Multistate Analysis
Details   Bayesian synthesis design and multistate analysis of remdesivir results showing 31% [18-44%] lower risk of death and 10% [1-18%] higher recovery.
Late Aghajani et al., Journal of Medical Virology, doi:10.1002/jmv.27053 (Peer Reviewed) death, ↓18.6%, p=0.49 Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19
Details   Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results for HCQ, remdesivir, and favipiravir.
Late Mahajan et al., Indian Journal of Anasthesia, doi:10.4103/ija.IJA_149_21 (Peer Reviewed) death, ↑76.5%, p=0.47 Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
Details   Small RCT with 34 remdesivir patients and 36 controls finding no significant difference in clinical outcomes.
Late Tsuzuki et al., medRxiv, doi:10.1101/2021.03.09.21253183 (Preprint) death, ↓8.8%, p=1.00 Efficacy of remdesivir in Japanese patients hospitalised with COVID-19: A large observational study using the COVID-19 Registry Japan
Details   Retrospective database analysis of 1907 hospitalized patients in Japan, using PSM to compare 74 remdesivir patients and 195 control patients, not showing significant differences in mortality and ventilation/ECMO, and showing signifcantly ..
Late Goldberg et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.02.029 (Peer Reviewed) hosp. time, ↓9.2%, p=0.77 A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary center in Israel
Details   Retrospective 29 remdesivir patients and 113 controls, not finding a significant difference in nasopharyngeal viral load or hospitalization time. Hospitalization time was lower with treatment, with a larger reduction for non-intubated pat..
Late Fateh et al., medRxiv, doi:10.1101/2021.03.05.21251351 (Preprint) A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations
Details   Retrospective 324 hospitalized patients in Iran reporting on the use Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations. There is no control group in this study, however authors suggest t..
Safety Touafchia et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.02.013 (Peer Reviewed) safety analysis Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns
Details   Comparison of bradycardia in COVID-19 patients treated with remdesivir compared to those treated with HCQ, lopinavir/ritonavir, tocilizumab or glucocorticoids, finding increased risk of bradycardia with remdesivir.
N/A Shen et al., Fundamentals of Clinical Pharmacology, doi:10.1111/fcp.12643 (Peer Reviewed) safety analysis Remdesivir potently inhibits carboxylesterase‐2 through covalent modifications: signifying strong drug‐drug interactions
Details   Analysis finding that remdesivir at nanomolar concentrations inhibits carboxylesterase‐2 (CES2) through covalent modifications. CES2 is a major drug‐metabolizing enzyme. Authors conclude that caution must be exercised when remdesivir is u..
In Vitro Jeffreys et al., bioRxiv, doi:10.1101/2020.12.23.424232 (Preprint) (In Vitro) in vitro Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2
Details   In Vitro study showing enhanced antiviral activity of ivermectin and remdesivir in combination.
Late Ullah et al., International Journal of Sciences, doi:10.18483/ijSci.2417 (Peer Reviewed) death, ↑100%, p=0.33 Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore
Details   Small late stage (hospitalized, <12 days symptoms) remdesivir study showing non-statistically significant higher mortality with treatment. No adjustments were made for differences in the groups. Remdesivir mean age was 49 vs. control 57...
Late Garibaldi et al., medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint) death, ↓20.0%, p=0.44 Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19
Details   Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality.
Late Flisiak et al., medRxiv, doi:10.1101/2020.10.30.20215301 (Preprint) death, ↓48.9%, p=0.18 Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study
Details   Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant).
Late Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130 (Preprint) death, ↓47.0%, p<0.001 Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository
Details   Retrospective database analysis of 7,816 Veterans Affairs hospitalized patients showing 47% reduction in progression from ARDS to mortality.
Late SOLIDARITY Trial Consortium, NEJM, doi:10.1056/NEJMoa2023184 (preprint 10/15) (Peer Reviewed) death, ↓5.0%, p=0.53 Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Details   WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) Remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p=0.50. Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p = 0.13.
Late Beigel et al., NEJM, doi:10.1056/NEJMoa2007764 (Peer Reviewed) death, ↓27.0%, p=0.07 Remdesivir for the Treatment of Covid-19 — Final Report
Details   RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29, p<0.001. Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio H..
Late Fried et al., Clinical Infectious Disease, doi:10.1093/cid/ciaa1268 (Peer Reviewed) death, ↓61.2%, p=0.02 Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States
Details   Database analysis of 11,721 hospitalized patients, 48 treated with remdesivir. Data inconsistencies have been found in this study, for example 99.4% of patients treated with HCQ were treated in urban hospitals, compared to 65% of untreat..
Late Pasquini et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkaa321 (Peer Reviewed) death, ↓16.2%, p<0.0001 Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU
Details   Retrospective 51 ICU patients under mechanical ventilation, 25 treated with remdesivir, showing lower mortality with treatment.
Late Spinner et al., JAMA, doi:10.1001/jama.2020.16349 (Peer Reviewed) death, ↓34.9%, p=0.50 Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial
Details   Late stage (median 8 days from symptom onset) RCT 584 patients with moderate COVID-19 showing (non-statistically significant) lower mortality. 5-day remdesivir had significantly higher odds of a better clinical status distribution on the..
Late Olender et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaa1041 (Peer Reviewed) death, ↓58.8%, p=0.001 Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
Details   Comparative analysis between remdesivir trial GS-US-540–5773 and a retrospective SOC cohort with similar inclusion criteria, showing lower mortality and higher recovery at day 14 with remdesivir.
Late Dubert et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.093 (Peer Reviewed) Case report study of the first five COVID-19 patients treated with remdesivir in France
Details   Early report on 5 ICU patients treated with remdesivir highlighting issues with usage in critically ill patients.
Late Zhu et al., medRxiv, doi:10.1101/2020.06.22.20136531 (Peer Reviewed) (meta analysis) death, ↓36.0%, p=0.02 Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
Details   Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175).
Late Goldman et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed) Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Details   RCT of remdesivir for 5 or 10 days with no placebo control group, showing no significant differences between 5 and 10 day treatment. NCT04292899
Late Wang et al., Lancet, doi:10.1016/S0140-6736(20)31022-9 (Peer Reviewed) death, ↑8.6%, p=1.00 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Details   Small RCT with 237 hospitalized patients in China with severe COVID-19, not showing statistically significant benefits. 158 treatment patients and 79 control patients. While too small for significance, the subgroup treated within 10 days..
Late Grein et al., NEJM, doi:10.1056/NEJMoa2007016 (Peer Reviewed) Compassionate Use of Remdesivir for Patients with Severe Covid-19
Details   Report on compassionate use of remdesivir with 61 severe COVID-19 patients, showing clinical improvement in 36 of 53 patients.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.